Repeat Interferon γ Release Assay Use in US Community Healthcare Organizations
Open Forum Infectious Diseases · 31.10.2026 · 13 (11)
DOI: 10.1093/ofid/ofag672 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 10.10.2026. Verfasst von Jeffrey I Campbell und 16 weiteren Autor:innen. Beteiligte Einrichtung: Section of Pediatric Infectious Diseases, Department of Pediatrics, Boston Medical Center, Boston, Massachusetts, USA. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, Robert Wood Johnson Foundation, Boston University Clinical and Translational Science Institute.
Abstract (Originalsprache)
Background
Interferon γ release assays (IGRAs) are the preferred test for tuberculosis infection in the United States. Their results can fluctuate from positive to negative (reversion), but there is limited information about who does or should receive repeat testing in routine clinical care.
Methods
We performed a retrospective cohort study of all individuals with a positive IGRA result in a US community health organization network (OCHIN). We characterized the frequency and predictors of repeat testing and reversion. We used published recommendations to classify repeat IGRAs as “likely,” “possibly,” and “probably not” indicated, and we estimated repeat IGRA overuse and underuse.
Results
Among 65 728 individuals with a positive IGRA result, 8978 (13.7%) had ≥1 subsequent test. Of the 8174 second tests with full results available for analysis, 6176 (75.6%) remained positive, 1904 (23.3%) reverted to negative, and 94 (1.2%) were uninterpretable. Lower odds of reversion were associated with higher initial Antigen minus Nil (Ag-Nil) value (adjusted odds ratio, 0.38 [95% confidence interval, .32–.45] for Ag-Nil 0.70 to <1.00, and 0.06 [.05–.07] for Ag-Nil ≥1.00 vs 0.35 [vs Ag-Nil 0.35 to <0.70 IU/mL]), and birth in a country with versus birth in a country without elevated tuberculosis incidence (adjusted odds ratio, 0.59 [95% confidence interval, .52–.67]). Of all repeat tests, 40.0% were likely indicated, 9.0% were possibly indicated, and 51.0% were probably not indicated.
Conclusions
Approximately 1 in 7 individuals with positive IGRA results had repeat testing. Most repeat tests were probably not indicated according to our utilization classification, whereas nearly half of individuals without a repeat test may have benefited from one.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of Pediatric Infectious Diseases, Department of Pediatrics, Boston Medical Center, Boston, Massachusetts, USA.
- Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, USA.
- Division of Epidemiology, University of California Berkeley School of Public Health, Berkeley, California, USA.
- Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
- Section of Infectious Diseases, Department of Medicine, Boston Medical Center, Boston, Massachusetts, USA.
- Department of Pediatrics, Boston Medical Center, Boston, Massachusetts, USA.
ORCID-Profile: Jeffrey I Campbell, Meredith B Brooks, Matthew Murrill, Jenine Dankovchik, Rachel Epstein, Jonathan Bressler, Heather Angier, Cynthia A Tschampl
Förderung
- NIAID NIH HHS
- Robert Wood Johnson Foundation
- Boston University Clinical and Translational Science Institute
- National Institute of Allergy and Infectious Diseases, National Institutes of Health
Zitieren
APA
Campbell, J. I., Brooks, M. B., Martinez, L., Murrill, M., Sinha, P., Martey, E., Giebultowicz, S., Dankovchik, J., Falkenstein, A., Epstein, R., Bressler, J., Angier, H., Haberer, J. E., Tschampl, C. A., Horsburgh, C. R., Jenkins, H. E., & Jacobson, K. R. (2026). Repeat Interferon γ Release Assay Use in US Community Healthcare Organizations. Open Forum Infectious Diseases, 13(11). https://doi.org/10.1093/ofid/ofag672
Vancouver
Campbell JI, Brooks MB, Martinez L, Murrill M, Sinha P, Martey E, et al. Repeat Interferon γ Release Assay Use in US Community Healthcare Organizations. Open Forum Infectious Diseases. 2026;13(11). doi:10.1093/ofid/ofag672
BibTeX
@article{Campbell2026,
author = {Campbell, Jeffrey I and Brooks, Meredith B and Martinez, Leonardo and Murrill, Matthew and Sinha, Pranay and Martey, Emily and Giebultowicz, Sophia and Dankovchik, Jenine and Falkenstein, Angelica and Epstein, Rachel and Bressler, Jonathan and Angier, Heather and Haberer, Jessica E and Tschampl, Cynthia A and Horsburgh, C Robert and Jenkins, Helen E and Jacobson, Karen R},
title = {Repeat Interferon γ Release Assay Use in US Community Healthcare Organizations},
journal = {Open Forum Infectious Diseases},
year = {2026},
volume = {13},
number = {11},
doi = {10.1093/ofid/ofag672}
}
EUVIMED